Severity-Adjusted Probability of Being Cost Effective-Reference-Cited by-同舟云学术

Severity-Adjusted Probability of Being Cost Effective

Published:2019-05-27 Issue:9 Volume:37 Page:1155-1163
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Versteegh Matthijs M.^ORCID,Ramos Isaac Corro,Buyukkaramikli Nasuh C.,Ansaripour Amir,Reckers-Droog Vivian T.,Brouwer Werner B. F.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-019-00810-8.pdf

Reference29 articles.

1. Ramos IC, Versteegh MM, de Boer RA, Koenders JM, Linssen GC, Meeder JG, Rutten-van Mölken MP. Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan for patients with chronic heart failure and reduced ejection fraction in the Netherlands: a country adaptation analysis under the former and current Dutch Pharmacoeconomic Guidelines. Value Health. 2017;20(10):1260–9. https://doi.org/10.1016/j.jval.2017.05.013 .

2. ACP public meeting 05-04-2019. https://www.zorginstituutnederland.nl/binaries/zinl/documenten/adviezen/2019/04/05/acp-advies-over-venetoclax/ACP-advies+over+venetoclax.pdf . Accessed 23 Apr 2019.

3. Shah KK. Severity of illness and priority setting in healthcare: a review of the literature. Health Policy. 2009. https://doi.org/10.1016/j.healthpol.2009.08.005 .

4. Wailoo A, Tsuchiya A, McCabe C. Weighting must wait. Pharmacoeconomics. 2009. https://doi.org/10.2165/11314100-000000000-00000 .

5. van de Wetering EJ, Stolk EA, van Exel NJ, Brouwer WBF. Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. Eur J Health Econ. 2013;1:107–15. https://doi.org/10.1007/s10198-011-0346-7 .

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective;PLOS ONE;2024-09-06

2. Health Equity Considerations in Cost-Effectiveness Analysis: Insights from an Umbrella Review;ClinicoEconomics and Outcomes Research;2024-08

3. The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study;Value in Health;2024-08

4. Framework for developing cost-effectiveness analysis threshold: the case of Egypt;Journal of the Egyptian Public Health Association;2024-06-03

5. Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran;Clinical Cardiology;2024-06